Fatal outcome of nevirapine-associated toxic epidermal necrolysis

International Journal of STD and AIDS

Volumn 19, Issue 9, 2008, Pages 642-643

  Leng, Katharina ^a,c   Lonsdorf, A ^b   Hartmann, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Pediatric Oncology Branch   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

HIV; Nevirapine; Rash; TEN

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; CROSS ALLERGY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACULOPAPULAR RASH; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 50849113140     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008062     Document Type: Article

References (7)

1. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8
2. Kong HH, Myers SA. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Dermatol Ther 2005;18:58-66
3. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21:264-5
4. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
5. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003;83:1-9
6. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001;44:354-7
7. Nordstrom BL, Norman HS, Dube TJ, Wilcox MA, Walker AM. Identification of abacavir hypersensitivity reaction in health care claims data. Pharmacoepidemiol Drug Saf 2007;16:289-96